Journal of Law and the Biosciences最新文献_第2页

Two-faced Janus? Consent to participate in research and consent to data processing in the EHDS era: a comparative analysis of requirements and standards in eight European countries. 双面Janus吗?EHDS时代参与研究的同意和数据处理的同意：八个欧洲国家要求和标准的比较分析。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-05-18 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag016

Luca Marelli, Ilaria Colussi, Irene Schlünder, Anne Bahr, Isabelle Huys, Dorota Krekora-Zając, Jan Kuráň, Teodora Lalova-Spinks, Deborah Mascalzoni, Mihaela Matei, Pilar Nicolás, Tom Southerington

{"title":"Two-faced Janus? Consent to participate in research and consent to data processing in the EHDS era: a comparative analysis of requirements and standards in eight European countries.","authors":"Luca Marelli, Ilaria Colussi, Irene Schlünder, Anne Bahr, Isabelle Huys, Dorota Krekora-Zając, Jan Kuráň, Teodora Lalova-Spinks, Deborah Mascalzoni, Mihaela Matei, Pilar Nicolás, Tom Southerington","doi":"10.1093/jlb/lsag016","DOIUrl":"https://doi.org/10.1093/jlb/lsag016","url":null,"abstract":"This study examines the complex and often ambiguous conceptualization of consent in European health research, focusing on the relationship between informed consent to participate in research and consent as a legal basis for personal data processing. Differences between these two forms of consent may lead to inconsistent procedures and requirements, thereby generating legal and practical challenges for researchers, ethics committees, data protection authorities, and other oversight bodies. Drawing on two use cases involving observational retrospective studies, the paper compares consent requirements and oversight practices in Belgium, the Czech Republic, Finland, France, Germany, Italy, Poland, and Spain, highlighting persistent fragmentation and uneven institutional coordination across national research governance systems. The paper also distinguishes between 'monist' conceptions of consent, which view research and data protection consent as expressions of a single normative concept, and 'dualist' conceptions, which treat them as distinct forms of authorization grounded in different ethical and legal rationales. The paper concludes by reflecting on the implications of the upcoming European Health Data Space Regulation, arguing that its approach to secondary data use may further accentuate existing tensions and highlighting the need for greater conceptual clarity and institutional coordination in European health research governance.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag016"},"PeriodicalIF":2.4,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147977568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polygenic disease risk scoring and genetic non-discrimination. 多基因疾病风险评分与基因非歧视。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-05-14 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsaf016

Jin K Park, Susannah Baruch, I Glenn Cohen

{"title":"Polygenic disease risk scoring and genetic non-discrimination.","authors":"Jin K Park, Susannah Baruch, I Glenn Cohen","doi":"10.1093/jlb/lsaf016","DOIUrl":"https://doi.org/10.1093/jlb/lsaf016","url":null,"abstract":"The Genetic Information Nondiscrimination Act (GINA) became law almost two decades ago, when genomic medicine was still in its infancy. One reason for its passage was to ensure that individuals and society would reap the benefits of emerging advances in genetic medicine, and would be able to benefit from genetic testing and research without fear of employment or health insurance discrimination. Since then, genomics has matured into a complex probabilistic science that increasingly allows for individualized estimates of genetic risk derived from large-scale population studies. Polygenic risk scores (PGSs), which provide genome-wide estimates of disease liability and may help indicate effective preventive care for an individual, raise new benefits but also concerns. PGS testing may become common in clinical practice, particularly to mitigate common complex diseases such as cardiac conditions and cancer. But are existing antidiscrimination protections adequate for a world where polygenic risk scoring is the norm? In this paper, we consider how existing laws apply and whether new legal and policy approaches are needed to support widespread, beneficial clinical use of PGSs. We also propose avenues for potential action by policymakers.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsaf016"},"PeriodicalIF":2.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13174347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Taking actuarial fairness seriously: what is required for the ethical use of genetics in insurance? 认真对待精算公平：在保险中道德地使用遗传学需要什么？

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-05-14 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag017

Harisan Nasir, Benjamin E Berkman, Leila Jamal, Chloe Connor, Anya E R Prince

{"title":"Taking actuarial fairness seriously: what is required for the ethical use of genetics in insurance?","authors":"Harisan Nasir, Benjamin E Berkman, Leila Jamal, Chloe Connor, Anya E R Prince","doi":"10.1093/jlb/lsag017","DOIUrl":"https://doi.org/10.1093/jlb/lsag017","url":null,"abstract":"Whether life insurers should be able to consider genetic information during underwriting is a long-standing debate often characterized by strong opinions on both sides. Insurers push for full access to applicants' genetic information, and consumer advocates often call for a ban on insurer use of the information. Both sides employ concepts of fairness and discrimination in supporting their position. This article considers the concept of actuarial fairness, where individuals are expected to pay for the risks they bring to an insurance pool. Currently, law and policy adopting this standard most often take a deferential approach, allowing insurers to utilize genetic information with wide latitude. This article takes seriously a middle-ground approach, broadly labeled as actuarial utility. Building from prior literature examining this issue, this article proposes a framework US policy can adopt to assist in the assessment of the actuarial utility of genetic information with a particular focus on emerging genetic technologies.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag017"},"PeriodicalIF":2.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13174401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind, machine, and the law: reimagining neurotechnology governance through disability rights. 思维、机器和法律：通过残疾人权利重新构想神经技术治理。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-05-14 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag011

Francisco Bariffi

{"title":"Mind, machine, and the law: reimagining neurotechnology governance through disability rights.","authors":"Francisco Bariffi","doi":"10.1093/jlb/lsag011","DOIUrl":"https://doi.org/10.1093/jlb/lsag011","url":null,"abstract":"The convergence of neurotechnologies and disability raises urgent questions about autonomy, mental integrity, and legal capacity for persons with disabilities. This article examines the human rights implications of emerging neurotechnologies-from brain-computer interfaces to cognitive monitoring tools-through the lens of the United Nations Convention on the Rights of Persons with Disabilities (CRPD). Drawing on historical abuses under the medical model of disability, it argues that the uncritical deployment of neurotechnologies risks replicating patterns of coercion, paternalism, and exclusion. By advancing a normative framework rooted in the CRPD and the social model of disability, the article proposes legal and ethical safeguards to protect mental privacy, ensure informed consent, and affirm supported decision-making. It calls for regulatory and design paradigms that shift from enhancement and correction to inclusion and empowerment. Ultimately, the article contends that disability rights must be at the center of neurotechnologies governance to prevent ableist harms and foster equitable innovation.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag011"},"PeriodicalIF":2.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13174384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patents, genetic resources, and traditional knowledge: the WIPO treaty and the global access and benefit-sharing regime complex. 专利、遗传资源和传统知识：知识产权组织条约与全球获取和惠益分享制度的复杂性。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-05-06 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag015

Frédéric Perron-Welch

{"title":"Patents, genetic resources, and traditional knowledge: the WIPO treaty and the global access and benefit-sharing regime complex.","authors":"Frédéric Perron-Welch","doi":"10.1093/jlb/lsag015","DOIUrl":"https://doi.org/10.1093/jlb/lsag015","url":null,"abstract":"The WIPO Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge (GRATK Treaty) represents a significant doctrinal development in international intellectual property (IP) law. It introduces a mandatory disclosure requirement obliging patent applicants to indicate the origin or source of genetic resources and associated traditional knowledge on which claimed inventions are based. This article situates the GRATK Treaty within the global access and benefit-sharing (ABS) regime complex, examining its interaction with the Convention on Biological Diversity and Nagoya Protocol. It argues that the Treaty constitutes a path-dependent yet normatively consequential response to the problem of biopiracy, strengthening procedural transparency within the patent system while maintaining coherence with existing international legal regimes. By analyzing its disclosure, sanctions, mutual supportiveness, and institutional provisions, the article demonstrates that the GRATK Treaty consolidates the benefit appropriation sub-regime despite not creating any new IP rights. Although its effectiveness will depend on ratification and implementation by major patent jurisdictions, the Treaty marks an incremental but important step toward reconciling IP governance with core elements of the global ABS regime.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag015"},"PeriodicalIF":2.4,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tear down the wall: why requiring the FDA and the PTO to share information will improve the decision-making of both agencies. 推倒墙：为什么要求FDA和PTO共享信息将改善这两个机构的决策。

IF 3.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-04-30 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag007

Robin Feldman, Gideon Schor

{"title":"Tear down the wall: why requiring the FDA and the PTO to share information will improve the decision-making of both agencies.","authors":"Robin Feldman, Gideon Schor","doi":"10.1093/jlb/lsag007","DOIUrl":"10.1093/jlb/lsag007","url":null,"abstract":"An invisible wall separates the U.S. Food and Drug Administration (FDA) from the U.S. Patent and Trademark Office (PTO). This wall blocks inter-agency communication, depriving the PTO of information relevant to patent applications and depriving the FDA of information relevant to drug-approval applications. Consequently, it is too easy for a drug company to tell the PTO 'our drug is new' (in hopes of speeding a patent grant) while telling the FDA 'our drug is not new' (in hopes of speeding drug approval). Better communication between the FDA and PTO would increase agency accuracy by preventing inconsistent representations, and would increase agency efficiency by avoiding informational asymmetry and duplication of effort. Presidents Obama and Trump created enhanced mechanisms that allow the PTO to receive information from counterparts in foreign countries and from industry about what is truly innovative. It would also be helpful for the PTO to enjoy the expertise of its own sister agency, located down the road. Despite scholarly and governmental proposals to mandate cooperation between the FDA and the PTO, such coordination remains limited in practice. This article proposes to break through the invisible wall between the FDA and the PTO, and to open pathways for communication between the two agencies.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag007"},"PeriodicalIF":3.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic testing fraud trends. 基因检测欺诈趋势。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-04-29 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag012

Jordan Paradise, Alyssa Valentine, Sara Cherny, Christina Ramesh

{"title":"Genetic testing fraud trends.","authors":"Jordan Paradise, Alyssa Valentine, Sara Cherny, Christina Ramesh","doi":"10.1093/jlb/lsag012","DOIUrl":"https://doi.org/10.1093/jlb/lsag012","url":null,"abstract":"Genetic testing fraud schemes are widespread, impacting patients, healthcare providers, and the US government. Fueled by rapid innovations in genetic testing capabilities and expansion of telehealth services following the pandemic, fraudsters are thriving. The Department of Justice (DOJ) and the Department of Health and Human Services (HHS) enhanced scrutiny of such fraud schemes over a decade ago, and in September 2019, targeted enforcement began with the indictment of 35 individuals on allegations of genetic testing fraud activities totaling $2.1 billion (https://www.justice.gov/archives/opa/pr/federal-law-enforcement-action-involving-fraudulent-genetic-testing-results-charges-against). By the end of 2024, the DOJ and HHS had initiated hundreds of investigations, with litigation across multiple legal jurisdictions involving physicians, telemedicine companies, marketing companies, and genetic testing laboratories. This article investigates the nature and scope of genetic testing fraud and describes the concerted government activity to thwart the proliferation of these schemes. While the actual mechanisms to carry out genetic testing fraud, such as kickbacks and inappropriate coding, are not new, there are multiple characteristics that make this type of healthcare fraud distinctive. We describe three genetic testing features that make genetic testing fraud unique and heighten the potential for fraud on the government: widespread interest in test content; test complexity; and associated billing challenges. The article further contributes to the literature by assessing genetic testing fraud schemes and discussing implications for physicians and the healthcare system, including recommendations to prevent future genetic testing fraud.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag012"},"PeriodicalIF":2.4,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biosecurity in the age of synthetic nucleic acids: modernizing the law to manage emerging threats. 合成核酸时代的生物安全：使法律现代化以管理新出现的威胁。

IF 3.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-04-28 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag005

Ayelet Berman

{"title":"Biosecurity in the age of synthetic nucleic acids: modernizing the law to manage emerging threats.","authors":"Ayelet Berman","doi":"10.1093/jlb/lsag005","DOIUrl":"10.1093/jlb/lsag005","url":null,"abstract":"The rapid expansion of synthetic biology has transformed research and innovation but has also created profound biosecurity challenges. Synthetic nucleic acid (SNA) technologies, which allow genetic material to be synthetically created, enable scientific progress but also lower the barriers to constructing or enhancing dangerous pathogens. This article argues that the governance of SNA should be grounded in a transnational new governance approach that combines binding international obligations with harmonized technical standards. It assesses the fitness of current regimes-the International Health Regulations, the Biological Weapons Convention (BWC), UN Security Council Resolution (UNSCR) 1540, and national biosecurity laws-and finds that while these instruments already impose binding obligations to prevent misuse of biological agents, their terms remain outdated and their application fragmented. Most states lack explicit SNA order screening requirements, and voluntary private standards such as those of the International Gene Synthesis Consortium and ISO 20688-2 remain inadequate for managing this global risk. The article recommends modernizing international law by clarifying that existing treaties cover synthetic biology, developing harmonized global screening standards, and updating national legislation to mandate and incentivize SNA order screening. It further proposes leveraging market access and funding power to drive global practice. Ultimately, safeguarding innovation in the age of SNA requires aligning law to manage the risks of emerging biotechnologies.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag005"},"PeriodicalIF":3.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147790373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alabama's LePage decision, the future of ex vivo embryos, and more. 阿拉巴马州LePage案的判决，体外胚胎的未来等等。

IF 3.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-04-20 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag013

Henry T Greely

{"title":"Alabama's LePage decision, the future of ex vivo embryos, and more.","authors":"Henry T Greely","doi":"10.1093/jlb/lsag013","DOIUrl":"10.1093/jlb/lsag013","url":null,"abstract":"In February 2024 the Alabama Supreme Court held that the destruction of frozen embryos stored at an in vitro fertilization (IVF) center could be the basis of a wrongful death suit by the prospective parents under Alabama law. The opinion caused a bipartisan uproar that led to its effective overturning by the Alabama legislature and governor 19 days after it was issued. The Alabama Supreme Court's unexpected intervention in IVF shows the surprising ways a mishap in a clinic can trigger a collision of originalist jurisprudence, judicial rhetoric, political mobilization, and media amplification in our post-Dobbs world. A closer look reminds us of how variable court systems and laws are across the USA, as well as the complex motivations of patients and others involved in assisted reproduction. It also shows how state court decisions, perhaps through intentional provocations, can reverberate in the national debate, leading to overreactions, some far beyond their jurisdictions' borders. Plus, in context, beyond the online quips, the political soundbites, and the media articles, it is a fascinating tale and all of that from a case that could easily have been decided, in either direction, as a low-key interpretation of a unique Alabama statute, without broad consequences.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag013"},"PeriodicalIF":3.4,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147790428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Augmented inventorship: rethinking patent law in the age of generative AI. 增强发明：在生成式人工智能时代重新思考专利法。

IF 2.4 2区哲学

Journal of Law and the Biosciences Pub Date : 2026-03-31 eCollection Date: 2026-01-01 DOI: 10.1093/jlb/lsag014

Haim V Levy

{"title":"Augmented inventorship: rethinking patent law in the age of generative AI.","authors":"Haim V Levy","doi":"10.1093/jlb/lsag014","DOIUrl":"10.1093/jlb/lsag014","url":null,"abstract":"Generative artificial intelligence (AI) now participates in tasks constitutive of invention-problem framing, hypothesis generation, and design-yet patent doctrine remains anchored to a natural-person rule that offers limited guidance for AI-intensive workflows. This Article advances augmented inventorship, a conservative but operationally modern attribution doctrine that preserves human inventorship while making AI's generative role legible and auditable at the moment of conception. Drawing on an analogy to augmented immunology, the framework identifies two design criteria-directability (independent and substantive human intellectual judgment steering model behavior or selection) and traceability (a reviewable, claim-centered record linking human reasons to claim elements)-and translates them into a proportionate evidentiary practice: a Computational Traceability Report and a Human-Machine Contribution Statement. These instruments are content-rich but code-light. They support enablement and sufficiency, clarify claim drafting and construction, reduce prosecution and litigation error costs, and balance evidentiary transparency with trade-secret sensitivity through proportional disclosure. Situated within-and distinguished from-the growing literature on AI inventorship and disclosure, the doctrine aligns with existing law (US conception and significant-contribution standards; the UK's 'actual deviser'; EPC sufficiency) and is compatible with TRIPS disclosure norms. Rather than demanding 'more disclosure' in the abstract, augmented inventorship supplies an administrable grammar for human accountability in AI-assisted research.","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"13 1","pages":"lsag014"},"PeriodicalIF":2.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13037463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147596411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0